Evidence map›Paper›PMID 34996944›Full record

ArticleScientific reports2022

Improvement of the affinity of an anti-rat P2X4 receptor antibody by introducing electrostatic interactions.

Chinatsu Shinozaki, Keita Kohno, Mitsunori Shiroishi, Daisuke Takahashi, Yu Yoshikawa, Yoshito Abe, Kenji Hamase, Makoto Nakakido, Kohei Tsumoto, Kazuhide Inoue and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Chinatsu Shinozaki *Department of Protein Structure, Function and Design, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Keita Kohno *Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi, Fukuoka, 812-8582, Japan.
Mitsunori Shiroishi *Department of Protein Structure, Function and Design, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Daisuke TakahashiDepartment of Protein Structure, Function and Design, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Yu YoshikawaDepartment of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi, Fukuoka, 812-8582, Japan.
Yoshito AbeDepartment of Protein Structure, Function and Design, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Kenji HamaseDepartment of Drug Discovery and Evolution, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Makoto NakakidoDepartment of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
Kohei TsumotoDepartment of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
Kazuhide InoueDepartment of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi, Fukuoka, 812-8582, Japan. inoue@phar.kyushu-u.ac.jp.
Makoto TsudaDepartment of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi, Fukuoka, 812-8582, Japan. tsuda@phar.kyushu-u.ac.jp.
Tadashi UedaDepartment of Protein Structure, Function and Design, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. ueda@phar.kyushu-u.ac.jp.
Kyushu University · JPThe University of Tokyo · JPTokyo University of Science · JP

Funding

Japan Agency for Medical Research and Development JP18am0101094j, JP18dm0107064h, JP18mk0101081h, JP18fm0208030h, JP18fk0108073h, and JP18ak0101100hJapan Agency for Medical Research and Development JP21am0101091Japan Society for the Promotion of Science JP16H02420, JP19H05766, and JP20H02531Japan Society for the Promotion of Science JP26293129the JST CREST JPMJCR20H8
6 · The paper itself

Abstract

We have recently developed a mouse monoclonal antibody (12-10H) binding to the head domain region in rat P2X4 receptor (rP2X4R, which is crucial for the pathogenesis of neuropathic pain) expressed on the cell with the highest binding affinity (K

Indexed as

AnimalsAntibodies, MonoclonalAntibody AffinityAntibody SpecificityCell Line, TumorCHO CellsCricetulusDisease Models, AnimalHumansMaleMicrogliaMutationNeuralgiaProtein BindingProtein ConformationPurinergic P2X Receptor AntagonistsAntibodies, MonoclonalP2rx4 protein, ratPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X4

Identifiers

PMID34996944
PMCPMC8742113
OpenAlexW4206507857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.